Inve India ▾

Onesource Specialty Pharma share price & results

Onesource Specialty Pharma Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Pure-play specialty pharma CDMO making biologics, drug-device combos, sterile injectables and softgel capsules for global pharma clients.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue516 ₹ crore+37.2% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin32.0 %+4.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit57.0 ₹ crore+470.0% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity0.19 %−3.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-39.38 %−25.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)10.58 %−342.6 ptsFY Mar 2026 vs FY Mar 2024Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

1 of 3 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Onesource Specialty Pharma Limited management guidance track record on Inve: 15 targets tracked across analysed earnings calls (1 achieved, 2 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Net Debt StatusDebt Free by end of FY27
Call transcript, Q3 FY25 · 29 Jan 2025		Q3 FY25Q1 FY27:Not mentioned.
Call transcript, Q1 FY27 · 25 Jul 2026		Delayed
Annual Revenue Target$400 million by FY28
Call transcript, Q3 FY25 · 29 Jan 2025		Q3 FY25Q1 FY27:Reiterated FY28 outlook of $400 million organic revenue.
Call transcript, Q1 FY27 · 25 Jul 2026		On Track
FY26 Performance WarningFY26 will be a 'transition year' with a 'tepid' H1
Call transcript, Q4 FY25 · 6 May 2025		Q4 FY25Q4 FY26:Full-year FY26 results confirmed the transition year warning, with revenue declining 2% and EBITDA declining 35% YoY.
Call transcript, Q4 FY26 · 13 May 2026		Achieved

Source: Inve Guidance Tracker for Onesource Specialty Pharma Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Onesource Specialty Pharma Limited's 15 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,397.3 +4.74% · +₹63.2

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −23.8% 1Y

₹1.2k₹1.4k₹1.6k₹1.8kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 23 Jan 2026Q4 FY26 — 13 May 2026Q1 FY27 — 24 Jul 2026

1Y: ₹1,832.7 on 24 Oct 2025 → ₹1,397.3. High ₹1,877.8 (3 Nov 2025), low ₹1,114 (29 Jan 2026).

Previous close
₹1,334.1
Market cap
₹18.2k Cr
52-week range
₹1,114 – ₹1,877.8
One year
−22.74%
Return on equity (TTM to Sept 2026)
0.19%

Overview

Symbol
NSE:ONESOURCE
Exchange
NSE
Currency
INR

What Onesource Specialty Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

OneSource Specialty Pharma is a multi-modality contract development and manufacturing organisation (CDMO) that develops and manufactures complex pharmaceutical products for global pharmaceutical companies on a B2B, fee-for-service basis. Its offerings span biologics (microbial and mammalian drug substance), drug-device combinations (pens, cartridges, pre-filled syringes) such as GLP-1/semaglutide products, sterile injectables (vials, fill-finish) and oral technologies (soft gelatine capsules), manufactured across five regulatory-approved facilities. The business, formerly Stelis Biopharma, was formed by combining the identified CDMO and Soft Gelatin businesses carved out of Strides Pharma and now serves customers directly as well as via tolling arrangements with site operators.

Segments

  • Drug-Device Combinations (DDC)
  • Biologics
  • Sterile Injectables
  • Soft Gelatin Capsules (SGC)
Manufacturing facilities
5
Combined manufacturing area
~722,000 sq ft across 5 facilities
Global customers
75+
Workforce
1,600+ professionals
Service offerings / modalities
4 (DDC, Biologics, Sterile Injectables, Soft Gelatin Capsules)
Successful regulatory audits
210+ (since inception)
Founded 2007Headquarters Bengaluru, Karnataka, India Company website

How the price took the results

close before → close after

Q1 FY27
+2.1%
25 Jul
Q4 FY26
−2.2%
13 May
Q3 FY26
−19.6%
24 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Onesource Specialty Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Onesource Specialty Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Onesource Specialty Pharma Limited

Guides on how to read this kind of business and the numbers that matter.